Related Experiment Videos
Indications for daptomycin use in endocarditis and pacemaker lead infection and outcomes in Leeds, UK
1Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. jonathan.sandoe@leedsth.nhs.uk
Abstract:
Infective endocarditis now comprises an increasingly complex mixture of endocardial infections, with staphylococci as the predominant cause. Although vancomycin has been an important therapeutic option for several decades, reduced susceptibility is emerging. Daptomycin is a relatively new antimicrobial agent, approved for right-sided endocarditis, but the data for other forms of endocarditis are limited. Here we report clinical data from the Leeds Endocarditis Service (Leeds, UK) for 19 patients treated with daptomycin between January 2007 and December 2009. The majority of cases were caused by staphylococci. All patients were treated with 6 mg/kg with a median treatment duration of 29 days. In total, 53% of patients were cured with antimicrobial regimens, which included daptomycin. Four patients (21%) died during therapy or within 30 days of stopping treatment. The current series is representative of everyday clinical practice and reflects the current difficulties in managing endocarditis.
Insights
Daptomycin shows limited efficacy for complex infective endocarditis, with only 53% cure rates in Staphylococcus cases. This highlights challenges in managing this serious heart valve infection.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Infective endocarditis is a complex infection, frequently caused by staphylococci.
- Vancomycin, a traditional treatment, faces emerging resistance issues.
- Daptomycin is approved for right-sided endocarditis, but data for other forms remain limited.
Purpose of the Study:
- To evaluate the clinical outcomes of daptomycin treatment for infective endocarditis.
- To assess daptomycin's efficacy and safety in a real-world clinical setting.
Main Methods:
- Retrospective analysis of 19 patients treated with daptomycin (6 mg/kg) at the Leeds Endocarditis Service.
- Data collected between January 2007 and December 2009.
- Focus on staphylococcal infections and treatment duration (median 29 days).
Main Results:
- The majority of cases involved Staphylococcus infections.
- 53% of patients achieved a cure with daptomycin-containing regimens.
- A significant mortality rate of 21% was observed during or within 30 days of treatment.
Conclusions:
- Daptomycin demonstrates limited success in treating complex infective endocarditis, particularly staphylococcal cases.
- Current management of infective endocarditis remains challenging.
- Further research is needed to optimize treatment strategies for this severe condition.
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Cardiomyopathy II: Dilated Cardiomyopathy
Acute Pyelonephritis II: Diagnostic Studies and Management